Press Release For Immediate Release Cambridge, UK. Monday, 28 April 2014 – Oval Medical Technologies Limited (“Oval”) Oval and SOLIZE enter into collaboration on injection device development. Working together to accelerate product development in the growing auto-injector market. Oval Medical Technologies Ltd (Cambridge, UK) and SOLIZE Corporation (Tokyo, Japan) have agreed to collaborate together […]
Press Release For Immediate Release Oval Medical awarded Technology Strategy Board Smart funding award Cambridge, UK. 14 April 2014 – Oval Medical Technologies Limited (“Oval”) announced today they have received a Smart funding award from the UK’s innovation agency, the Technology Strategy Board, of £228,256 for a project that will progress the development of the […]
Oval Medical Technologies Limited (“Oval”), a leading auto-injector company, has named Dr. Paul Harper as Chairman of the Board. He will be succeeding Peter Keen after his three-year tenure. Peter has now taken the position of Chief Executive at investment fund Cambridge Innovation Capital. Dr Harper took up the role at Oval in January 2014, […]
Drug development pipelines are tending towards increasing numbers of injectable products, and amongst these an ever larger proportion are viscous biologics and sustained-release formulations.
Inclusive design has unique challenges because it aims to improve usability for a wide range of users. This typically includes people with lower levels of ability, as well as mainstream users. This paper examines the effectiveness of two methods that are used in inclusive design.
Oval Medical Technologies Ltd (‘Oval’) today announced that they have signed another deal following an initial feasibility study with a global pharmaceutical company, to a value in excess of one million pounds. The feasibility study, which primarily focused on the pharmaceutical drug’s stability in Oval’s standard primary drug container, started in March 2012 and completed […]